title: The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.
abstract: It is suggested that the bioavailability of CYP3A4 substrates might be low due to first-pass metabolism in the small intestine, and it is possible that P-glycoprotein (P-gp) may influence first-pass metabolism in a co-operative manner. We have collected information of the pharmacokinetics of CYP3A4 substrates to evaluate the fraction absorbed (Fa), intestinal availability (Fg) and hepatic availability (Fh) and have investigated the intestinal first-pass metabolism and the effect of P-gp on this. The pharmacokinetic data involved ten compounds metabolized by CYP3A4 in humans, with and without an inhibitor or inducer. FaFg, which is the product of Fa and Fg, and Fh were calculated using three liver blood flow rates (17.1, 21.4, 25.5 mL/min/kg) in consideration of variations in the liver flow rate. Co-administration with an inhibitor of CYP3A4 and treatment of an inducer of CYP3A4 caused an increase and decrease in the FaFg of CYP3A4 substrates, regardless of the liver blood flow, indicating that CYP3A4 substrates exhibit a first-pass effect in their metabolism. This holds true regardless of whether the compounds are P-gp substrates or not. No relationship was observed between FaFg and Fh, regardless of the hepatic blood flow rate and the P-gp substrates. The FaFg of both P-gp and non P-gp substrates decreased as the hepatic intrinsic clearance increased. FaFg was markedly reduced when the hepatic intrinsic clearance was more than 100 mL/min/kg. This in vivo intrinsic clearance corresponds to an in vitro intrinsic clearance of 78 muL/min/mg human hepatic microsomal protein, equivalent to a half-life of 8.9 min for the substrate in a commonly used metabolic stability test with human microsomes (1 mgMs protein/mL). This phenomenon was not observed in substrates of CYP isoforms other than CYP3A4. In conclusion, it is suggested that CYP3A4 substrates which have a hepatic intrinsic clearance of 100 mL/min/kg exhibit a low bioavailability due to intestinal first-pass metabolism, regardless of whether they are substrates of P-gp or not.
authors.affiliation: Pre-clinical Research Dept. I, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan. katomth@chugai-pharm.co.jp
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kato
authors.forename: Koji
authors.initials: K
authors.lastname: Chiba
authors.forename: Akihiro
authors.initials: A
authors.lastname: Hisaka
authors.forename: Michi
authors.initials: M
authors.lastname: Ishigami
authors.forename: Makoto
authors.initials: M
authors.lastname: Kayama
authors.forename: Naomi
authors.initials: N
authors.lastname: Mizuno
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nagata
authors.forename: Susumu
authors.initials: S
authors.lastname: Takakuwa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tsukamoto
authors.forename: Kaoru
authors.initials: K
authors.lastname: Ueda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kusuhara
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Ito
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sugiyama